InGeneron

18 articles about InGeneron

• InGeneron Announces Critical In-Depth Analysis of the Results from a Recently Published 480-Patient Phase III Knee Osteoarthritis Trial

  11/21/2023

  InGeneron, Inc., a clinical stage biotechnology company, announces a critical in-depth analysis of the results from a 480-patient Phase III knee osteoarthritis (OA) trial that was recently published in the Journal Nature Medicine on November 2nd, 2023.

• InGeneron Reports Positive Long-Term Results for its Cell Therapy in Partial-Thickness Rotator Cuff Tears

  11/13/2023

  InGeneron, Inc., a clinical-stage biotechnology company, today announced positive clinical trial data demonstrating long-term safety and efficacy of InGeneron’s cell therapy for treating partial-thickness rotator cuff tears.

• New Study Reports Broad Applicability of InGeneron’s Regenerative Cell Therapy System Across Patient Groups

  1/7/2023

  InGeneron, Inc., a clinical stage biotechnology company, announced the publication of a newly released study, titled “The composition of adipose-derived regenerative cells isolated from lipoaspirate using a novel point of care system does not depend on the subject's individual age, sex, body mass index and ethnicity”, published in the Journal Cells on December 21, 2022.

• InGeneron Publishes Overview on Current State and Potential of Regenerative Cell Therapy in Orthopedics

  1/24/2022

  InGeneron, Inc., a clinical stage biotechnology company, announced the publication of a succinct scientific review of regenerative cell therapy, commonly called “stem cell therapy”, to treat orthopedic indications.

• American Medical Association Issues New CPT® Category III Codes for InGeneron’s Cell Therapy for Rotator Cuff Tears

  1/6/2022

  InGeneron, Inc., a clinical stage biotechnology company, announced that the American Medical Association’s Current Procedural Terminology Editorial Panel has issued two new Category III CPT® codes for the company’s autologous, adipose-derived regenerative cell therapy for partial thickness rotator cuff tears.

• InGeneron Publishes Significant Support for the Existence of Naturally Pluripotent Stem Cells in All Organs in the Adult Body

  11/23/2021

  InGeneron, Inc., a clinical stage regenerative medicine and cell therapy company, announced the publication of the first comprehensive analysis providing significant support for the existence of naturally pluripotent stem cells in all organs.

• InGeneron Reports First-In-Human Microscopic Evidence of Adult Tendon Regeneration Following Autologous Stem Cell Treatment

  7/26/2021

  InGeneron, Inc. today announced the publication of the first-in-human comprehensive immunohistochemical evaluation of adult tendon repair following the local injection of fresh, uncultured, unmodified, utologous, adipose derived regenerative cells (UA-ADRCs).

• FDA-Approved Randomized Controlled Feasibility Study Finds InGeneron's Regenerative Cell Therapy to Significantly Reduce Pain and Improve Shoulder Function Over Corticosteroid Injection to Address Symptomatic Partial-Thickness Rotator Cuff Tears

  4/7/2020

  InGeneron announces publication of favorable results using regenerative cells isolated from patients’ own body fat prepared with the Transpose® RT System in the Journal of Orthopaedic Surgery and Research.

• InGeneron Announces Publication of Preclinical Results for its Cell Therapy in Chronic Ischemic Heart Failure

  10/31/2019

  Animal model for the study of Chronic Myocardial Infarction indicates, for the first time, regenerative potential in a pig’s heart using uncultured autologous adipose-derived regenerative cells prepared at point of care.

• InGeneron Extends Series D Financing to $43 Million to Bring Regenerative Cell Therapy into the Clinic

  6/11/2019

  Company raises up to additional $23 million from strategic partner Sanford Health to advance pivotal program in rotator cuff tendinopathy

• InGeneron Initiates Pivotal Study for its Clinical Lead Program in Rotator Cuff Tendinopathy

  5/15/2019

  Company enrolls first patients in multi-center trial evaluating regenerative cell therapy at the point of care for partial rotator cuff tears

• InGeneron Expands Development Pipeline with Two Osteoarthritis Programs

  1/23/2019

  Company enrolls first patients in feasibility studies for chronic back pain and wrist osteoarthritis, setting clinical development focus on orthopedic indications

• InGeneron Brings Aboard a New CEO

  10/4/2017

• InGeneron Announces Publication Of Positive Results From Investigator-Initiated Wound Healing Case Series Using Company’s Regenerative Cell Technology

  9/18/2017

• InGeneron Completes Strategic Financing From Sanford Health To Advance Regenerative Cell Therapies

  3/6/2017

• InGeneron CEO Steps Down, Hunt for New Leader Begins

  2/15/2017

• InGeneron Announces Changes In Management Team

  2/15/2017

• InGeneron Announces Presentation Of Results From Investigator Initiated Case Series Of Its Regenerative Cell Therapy In Chronic Back Pain At IFATS

  11/21/2016